At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 202 target
Drug / intervention
Adebrelimab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)
In Brief
A Phase 2 clinical trial evaluating Adebrelimab, Chemotherapy, and 1 other intervention for Small Cell Lung Cancer Extensive Stage. Currently recruiting, targeting 202 participants across 1 site.
Detailed Summary
Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined with Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmall Cell Lung Cancer Extensive Stage
CountriesChina
CollaboratorsShanghai Shengdi Pharmaceutical Co., Ltd
Timeline
Phase 2Recruiting
20252026202720282029
First PostedSep 2024
Enrollment StartDec 2024
TodayJul 2026
Primary CompletionDec 2026
Study CompletionDec 2028
First PostedSep 24, 2024
Enrollment StartDec 23, 2024
Primary CompletionDec 1, 2026
Study CompletionDec 1, 2028
TodayJul 1, 2026
Enrollment to primary: 1.9 yearsPosted 1.8 years agoPrimary completion in 5 months
Interventions
Adebrelimabdrug
Adebrelimab combined with chemotherapy synchronous LDRT
Chemotherapydrug
Chemotherapy
low dose radiotherapyradiation
low dose radiotherapy